The latest developments from suppliers of ingredients, development and manufacturing services, and related technologies for pharmaceutical and biopharmaceutical development and production.
Lonza has entered into a binding contractual agreement for the purchase of a sterile drug-product and fill–finish facility in Stein, Switzerland from Novartis. The sterile, multi-product facility currently serves as the Novartis Center of...
The latest news from CDMOs, CMOs, and suppliers featuring news from Seqens, Ampac, Wuxi, Catalent and Novavax.
Chemicals/Chemical API Manufacturing
Seqens to Open New Innovation and Development Center
Seqens, a contract development and...
Kit Check, a provider of automated medication management solutions for hospitals, has announced it has been accepted into a pilot program by the US Food and Drug Administration Act for evaluating package-level tracing and verification technology in...
The latest news from CDMOs, CMOs, and suppliers featuring news from Lonza, Piramal Pharma Solutions, Tergus Pharma, LSNE, Aptar, and Rentschler Fill Solutions.
Chemicals/Chemical API Manufacturing
Lonza To Expand HPAPI Development and Mfg...
Bristol-Myers Squibb (BMS) and Catalent have announced that Catalent has agreed to purchase BMS’ oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy.
The 19,300-square-meter Anagni plant has served as...
Otsuka Chemical, a manufacturer of chemicals, has agreed to acquire certain assets from Astellas Pharma relating to the active pharmaceutical ingredient (API), cefixime, a cephalosporin antibiotic.
Under the agreement, Otsuka will have rights to...
Fujifilm Corporation has announced an initial $10-million investment in a full-scale, fully integrated continuous processing facility for non-GMP manufacturing of biopharmaceuticals at the Billingham, UK site of Fujifilm Diosynth Biotechnologies,...
The latest news from CDMOs, CMOs, and suppliers featuring news from Thermo Fisher, Cambrex, Lonza, Vetter, Sterling Pharma, Fujifilm, PCI Pharma Services, Particle Sciences, Vibologics, iBio, and Parexel.
Chemicals/Chemical API...
Aldevron, a contract provider specializing in the production of nucleic acids, proteins, and antibodies, has announced expansion plans for a new 14-acre campus for gene and cell therapy manufacturing at its headquarters in Fargo, North Dakota....
Thermo Fisher Scientific has announced a $50-million investment in its global bioproduction capabilities to expand capacity for manufacturing single-use bioprocess container (BPC) systems at its site in Cramlington, United Kingdom and related...
WuXi Biologics, a contract biologics manufacturer, has signed a letter of intent for a strategic partnership with an unnamed vaccine maker for a 20-year supply contract, estimated to be worth more than $3 billion. Under the letter of intent, WuXi...
Catalent has completed its $1.2-billion acquisition of Paragon Bioservices, a contract provider of viral vector development and manufacturing services for gene therapies.
Paragon has development and manufacturing capabilities in adeno-associated...
The latest news from CDMOs, CMOs, and suppliers, featuring news from Fujifilm Diosynth Biotechnologies and Recipharma.
Biologics manufacturing
Fujifilm Diosynth Biotechnologies to Expand UK Site with New BioCampus
Fujifilm Diosynth...
WuXi Biologics, a contract biologics manufacturer, has begun construction of 1.3-million square foot manufacturing center in Chengdu, China, in southwest China.
The new integrated manufacturing center will include drug development and commercial...
Thermo Fisher Scientific has agreed to acquire a drug-substance manufacturing site in Cork, Ireland, from GlaxoSmithKline for approximately EUR 90 million ($100.6 million). Thermo says it will expand capacity at the Cork site for the development...
